Director of Chemistry Genentech South San Francisco, California
In addition to each of the factors that affect the identification of a successful oncology drug candidate, drug discovery aimed at treating neurological cancers must also consider the presence of the blood-brain-barrier (BBB). High expression of transporters at the BBB limits most kinase inhibitors from freely reaching CNS malignancies within the brain. This talk will discuss the unmet need for neuro-oncology treatments and the discovery of paxalisib (GDC-0084), a blood-brain barrier penetrating inhibitor of PI3 kinase.
Upon completion, participant will be familiar with the unique challenges associated with discovering small molecule drugs intended for targets in the CNS.
Upon completion, participant will be familiar with principles required to fairly assess preclinical CNS penetration of small molecule drugs.
Upon completion, participant will be familiar with design principles and approaches for discovering small molecule drugs for neuro-oncology.
Upon completion, participant will be familiar with the need and opportunities for small molecule drugs for the treatment of brain cancers.